key: cord-0757703-mpum5vzk
authors: Saiag, Esther; Grupper, Ayelet; Avivi, Irit; Elkayam, Ori; Ram, Ron; Herishanu, Yair; Cohen, Yael; Perry, Chava; Furer, Victoria; Katchman, Helena; Rabinowich, Liane; Ben-Yehoyada, Merav; Halperin, Tami; Baruch, Roni; Goldshmidt, Hanoch; Hagin, David; Ben-Ami, Ronen; Sprecher, Eli; Bomze, David
title: The effect of a third-dose BNT162b2 vaccine on anti-sars-cov-2 antibody levels in immunosuppressed patients
date: 2022-02-18
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2022.02.002
sha: 59f4782f08db7635ed4f582d6f301706d8cc4ca4
doc_id: 757703
cord_uid: mpum5vzk

OBJECTIVE: The recent surge in COVID-19 cases led to consideration of a booster vaccine in previously vaccinated immunosuppressed individuals. However, the immunogenic effect of a third-dose SARS-CoV-2 vaccine in immunosuppressed patients is still unknown. METHODS: This was an observational cohort study of 279 previously-vaccinated immunosuppressed patients followed at a single tertiary hospital in Israel. Patients were administered a third dose of the Pfizer-BioNTech mRNA vaccine (BNT162b2), between July 14(th) and July 21(st), 2021. Levels of IgG antibodies against the spike receptor-binding domain of SARS-CoV-2 were measured 3-4 weeks after vaccination. RESULTS: Of the cohort of 279 patients, 124 (44.4%) had haematologic malignancies, 57 (20.4%) had rheumatologic diseases, and 98 (35.1%) were solid organ-transplant recipients. Anti-SARS-CoV-2 antibody levels increased in 74.9% of cases. Across the entire cohort, the median absolute antibody levels (expressed in AU/mL) increased from 7 (IQR, 0.1-69) to 243 (IQR, 2-4749) after the booster dose. The response significantly varied across subgroups: the transplant cohort showed the greatest increase in absolute antibody levels (from 52 [IQR, 7.25-184.5] to 1824 [IQR 161-9686]), followed by the rheumatologic cohort (from 22 [IQR, 1-106] to 1291 [IQR, 6-6231]), and the haemato-oncological cohort (from 1 [IQR, 0.1-7] to 7.5 [IQR, 0.1-407.5]); χ(2)=8.30 for difference in fold-change (P=0.016). Out of 193 patients who were seronegative at baseline, 76 became seropositive after vaccination, corresponding to a 39.4% (95% CI, 32.8%-46.4%) seroconversion rate. Transplant patients had the highest seroconversion rate (58.3% [95% CI, 44.3%-71.2%]), followed by rheumatologic patients (44.1% [95% CI, 28.9%-60.5%]), and haemato-oncology patients (29.7% [95% CI, 22%-38.8%]; χ(2)=11.87; P=0.003). CONCLUSIONS: A third dose of BNT162b2 is immunogenic in most immunosuppressed individuals, although antibody response may differ based on the type of disease and immunosuppression. The antibody level that correlates with protection is still unknown, thus future studies are needed to evaluate clinical outcomes.

The Pfizer-BioNTech mRNA vaccine (BNT162b2) has a 90%-95% vaccine 2 effectiveness according to several large real-world studies. ( Immunogenicity was assessed via a chemiluminescent microparticle immunoassay 24 (SARS-CoV-2 IgG II Quant assay on the Alinity i system; Abbott, IL, USA), which is 25 used to quantify IgG antibody levels in patient sera. (8, 9) The assay detects IgG 26 antibodies against the receptor-binding domain (RBD) of the S1 subunit of the spike 27 protein of SARS-CoV-2 (anti-S), with 50 arbitrary units (AU)/mL as a positive cutoff and 28 an upper limit of quantification of 40,000 AU/mL, as defined by the manufacturer. The 29 results of this assay were shown to correlate with SARS-CoV-2 neutralisation in 30 vitro. (10) In order to calculate fold-change between levels before and after the third 31 dose, we replaced measurement values of 0 with 0.1. 32

The t-test or U-test were used to compare parametric or nonparametric continuous data 33 across two groups, respectively. The Kruskal-Wallis test was used to compare 34 nonparametric continuous data across three groups. The χ 2 test was used to identify 35 association between categorical variables. Pearson's correlation was used for testing 36 association between two continuous variables. Linear regression or logistic regression 37 were used to detect association between a set of covariates and a continuous or binary 38 J o u r n a l P r e -p r o o f outcome, respectively. The proportion of patients who developed an antibody response 39 is reported with point estimates, and confidence intervals were calculated using 40

Wilson's method. All tests were two-sided, setting a significance level of 0.05. All 41 statistical analyses were performed in R, version 3.5.0. 42

Overall, 279 immunosuppressed patients were vaccinated with a third BNT162b2 dose 44 ( clinical conditions within each cohort can be found in Table S3 . 52

All patients had their antibody levels measured at baseline, and a second sample was 53 obtained after 3-4 weeks (median 25 days) ( Figure 1A) . In general, antibody levels 54 (Figure 1C) . The fold-change after the booster dose was not 66 associated with sex, but was negatively correlated with age ( Figure S1) (Table S1) . 72

Out of 193 patients who were seronegative at baseline (anti-S IgG <50 AU/mL), 76 were 73 seropositive (anti-S IgG ≥50 AU/mL) after the vaccination, representing a 39.4% (95% 74 CI, 32.8%-46.4%) seroconversion rate ( Table 1 (B) Relative frequency of the fold-change in antibody levels following the booster dose. The highest fold-change is seen in the transplant cohort and the lowest fold-change is seen in the haemato-oncological cohort.

(C) Antibody levels before and after the booster dose. Each dot represents a single patient, and the median level is represented by the line in the box. Listed inside each panel is the percentage of seronegative patients at baseline who developed a positive antibody response (≥50 AU/mL) after the booster (i.e. seroconverted), which was highest in the transplant cohort and lowest in the haemato-oncological cohort. 

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel

Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

In-hospital mortality among immunosuppressed patients with COVID-19

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

SARS-CoV-2 Immunoassays: Advancing diagnostics of COVID-19

Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. The Lancet

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Antibody Response Fold-Change (median

E.Sa. and E.Sp. designed and conceived the study. E.Sa. and A.G. extracted the data. 

immunocompromised populations, including patients with haematologic malignancies, 85 rheumatologic diseases, or solid-organ transplants. The vaccine led to a median 18-fold 86 increase in antibody levels, measured three weeks after administration. To the best of 87 our knowledge, this is the first work that compares response to a booster dose across 88 different immunosuppressed subgroups, whose heterogeneity was reflected by a 

The authors do not have any conflicts of interest to disclose.Funding: Assay reagents were provided by Siemens company. The study did not receive any other funding.